Leena Elhussein
Overview
Explore the profile of Leena Elhussein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo Y, Raventos B, Catala M, Elhussein L, Lopez-Guell K, Tan E, et al.
Pharmacoepidemiol Drug Saf
. 2024 Oct;
33(10):e70022.
PMID: 39414581
Purpose: To illustrate the interest in using interrupted time series (ITS) methods, this study evaluated the impact of the UK MHRA's March 2019 Risk Minimisation Measures (RMM) on fluoroquinolone usage....
2.
Elhussein L, Robinson D, Delmestri A, Clegg A, Prieto-Alhambra D, Silman A, et al.
J Clin Epidemiol
. 2024 Jun;
173:111442.
PMID: 38942178
Objectives: Frailty is a dynamic health state that changes over time. Our hypothesis was that there are identifiable subgroups of the older population that have specific patterns of deterioration. The...
3.
Woodcock V, Chen J, Purshouse K, Butcher C, Collins L, Haddon C, et al.
BJUI Compass
. 2023 Apr;
4(3):322-330.
PMID: 37025470
Objectives: This study aimed to investigate the anti-PD-1 inhibitor pembrolizumab as a potential agent for use in non-muscle-invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run-in study to...
4.
Elhussein L, Jodicke A, He Y, Delmestri A, Robinson D, Strauss V, et al.
BMC Geriatr
. 2023 Feb;
23(1):58.
PMID: 36721104
Background: While several definitions exist for multimorbidity, frailty or polypharmacy, it is yet unclear to what extent single healthcare markers capture the complexity of health-related needs in older people in...
5.
Robinson D, Ali M, Strauss V, Elhussein L, Abrahamsen B, Arden N, et al.
Health Technol Assess
. 2021 Mar;
25(17):1-106.
PMID: 33739919
Background: Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack...
6.
Robinson D, Ali M, Pallares N, Tebe C, Elhussein L, Abrahamsen B, et al.
J Bone Miner Res
. 2020 Dec;
36(5):820-832.
PMID: 33373491
Bisphosphonates are the first-line treatment for preventing fractures in osteoporosis patients. However, their use is contraindicated or to be used with caution in chronic kidney disease (CKD) patients, primarily because...
7.
Ovseiko P, Taylor M, Gilligan R, Birks J, Elhussein L, Rogers M, et al.
BMJ
. 2020 Oct;
371:m3975.
PMID: 33106283
No abstract available.
8.
Virdee P, Marian I, Mansouri A, Elhussein L, Kirtley S, Holt T, et al.
Cancers (Basel)
. 2020 Aug;
12(9).
PMID: 32825191
Introduction: A full blood count (FBC) blood test includes 20 components. We systematically reviewed studies that assessed the association of the FBC and diagnosis of colorectal cancer to identify components...
9.
Brown N, Ng S, Brooks C, Coutts T, Holmes J, Roberts C, et al.
BMC Cancer
. 2020 Mar;
20(1):198.
PMID: 32164579
Background: Median survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide chemo-radiotherapy. The immune checkpoint inhibitor ipilimumab targets...
10.
Alarkawi D, Ali M, Bliuc D, Pallares N, Tebe C, Elhussein L, et al.
J Bone Miner Res
. 2020 Jan;
35(5):894-900.
PMID: 31968134
Oral bisphosphonates (oBPs) have been associated with reduced fractures and mortality. However, their risks and benefits are unclear in patients with moderate-severe CKD. This study examined the association between oBPs...